Voya Investment Management LLC Sells 5,439 Shares of Illumina, Inc. (NASDAQ:ILMN)

Voya Investment Management LLC cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 4.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 104,668 shares of the life sciences company's stock after selling 5,439 shares during the quarter. Voya Investment Management LLC owned 0.07% of Illumina worth $13,987,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Bank of Stockton raised its holdings in shares of Illumina by 3.8% during the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company's stock worth $289,000 after buying an additional 80 shares in the last quarter. Stephens Inc. AR raised its holdings in Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company's stock worth $885,000 after purchasing an additional 90 shares during the last quarter. Spire Wealth Management grew its holdings in Illumina by 26.0% during the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company's stock worth $63,000 after acquiring an additional 97 shares during the period. IFP Advisors Inc lifted its stake in Illumina by 19.1% in the fourth quarter. IFP Advisors Inc now owns 617 shares of the life sciences company's stock valued at $82,000 after buying an additional 99 shares during the period. Finally, Freedom Investment Management Inc. boosted its stake in Illumina by 3.7% during the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock worth $382,000 after acquiring an additional 101 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Price Performance

Shares of ILMN stock traded up $1.37 during trading hours on Friday, hitting $77.88. 1,190,592 shares of the company's stock were exchanged, compared to its average volume of 2,281,025. The company has a market capitalization of $12.33 billion, a PE ratio of -10.14, a PEG ratio of 1.60 and a beta of 1.38. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The business's 50 day simple moving average is $80.43 and its 200-day simple moving average is $116.34.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Citigroup cut their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. Piper Sandler boosted their price objective on Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and dropped their price objective for the company from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Robert W. Baird lowered their price target on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $137.55.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.